Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lexagene Holdings Inc LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in... see more

GREY:LXXGQ - Post Discussion

Lexagene Holdings Inc > New 5 minutes test for COVID-19 by Abott
View:
Comment by kh231 on Mar 29, 2020 9:37am
YIKES!!! Is this bad news for LXG ?!
Comment by Investor62 on Mar 29, 2020 10:18am
why bad news? LXG main business is not testing the COVID-19. Don't forget what the main usage will be: in their company presentation this is clearly shown. Main concentration is on the non-human medical tests: Veterinary Diagnostics ~ $5.4B Food Safety ~ $24.4B Open-Access Use > $10B This is a $40 billion market. Clinical Diagnostics ($12.9B) requires FDA approval, and that's what they& ...more  
Comment by EduardoSanchez on Mar 29, 2020 10:42am
The Abbott 5 minute PCR test is far from a sensitive test. It is achieves below 90% concordance. This type of test is generally used for diagnosing the flu which makes sense, but to diagnose Covid which is 20 X more lethal makes no sense. This test will not contain Covid. It goes to show how desperate the US is to get rapid testing. Here is an article from Science Daily showing results of a ...more  
Comment by BigBagofWeed on Mar 30, 2020 1:33pm
EVEN THOUGH ITS NOT ACCURATE AT LEAST ITS OUT THERE.  LXG IS SLEEPING AT THE WHEEL.
Comment by EduardoSanchez on Mar 30, 2020 1:33am
LexaGene’s technology is best designed for syndromic testing, where people want to identify the cause of infection (and how to treat it if we include antimicrobial assays).  In other words - applications where a high Plex is desirable.   The Abbott machine is used primarily for flu diagnoses. It is a machine that is designed to detect one specific target. COVID will become seasonal - ...more  
Comment by 007dave on Mar 30, 2020 11:01am
Great information again Mr Sanchez and I'm pretty sure the long term holders believe in Dr Regan and the LX2 capabilities big BUT here is Lexagene seems to be slow to the party and in recent new releases the information seems vague. I've said it before just be clear and concise. " Yes Lexagene has developed not is developing and give us and the market a start date for manufacturing ...more  
Comment by letsdoit on Mar 30, 2020 11:24am
You can have the best product in the world but if you are clueless on how to run a business then it don't matter a dime, can't blame the big shareholder for selling, this is no way to run a Business, geeks with a decent machine won't wow Wall Street, I'm selling up, I'm done man
Comment by 007dave on Mar 30, 2020 12:54pm
Can't disagree. Also can't wow Wall Street with a TSX Venture listing either. Should have gone for Nasdaq listing months ago.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities